Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion.

IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Climacteric Pub Date : 2024-11-06 DOI:10.1080/13697137.2024.2418503
Angelo Cagnacci, Paola Villa, Giuseppina Paola Grassi, Nicoletta Biglia, Marco Gambacciani, Costantino Di Carlo, Francesca Nocera, Salvatore Caruso, Angelamaria Becorpi, Stefano Lello, Anna Maria Paoletti
{"title":"Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion.","authors":"Angelo Cagnacci, Paola Villa, Giuseppina Paola Grassi, Nicoletta Biglia, Marco Gambacciani, Costantino Di Carlo, Francesca Nocera, Salvatore Caruso, Angelamaria Becorpi, Stefano Lello, Anna Maria Paoletti","doi":"10.1080/13697137.2024.2418503","DOIUrl":null,"url":null,"abstract":"<p><p>The specific Italian Group of Study of the Menopause formulated a consensus opinion on the use of estrogen therapy (ET) or combined estro-progestin hormone therapy (HT) after breast and gynecological cancers. This consensus is based on the risk of recurrence of the specific cancer during ET/HT, the presence of steroid receptors in cancer cells, the use of adjuvant hormone therapies and data on the use of ET/HT after cancer. The following positions were reached. ET/HT can be used after vulvar cancers and melanoma, but with great caution after the rare adenocarcinomas. ET/HT can be used after cervical cancer, but ET should be used with caution after adenocarcinomas. ET/HT can be used after International Federation of Obstetrics and Gynecology (FIGO) stage I-II estrogen-dependent endometrial cancers, except in Black women, and can probably be used after estrogen-independent endometrial cancers. ET/HT cannot be administered or should be used with great caution after most uterine sarcomas. ET/HT can probably be used after ovarian neoplasms except for granulosa cell tumors, and with great caution after low-grade serous ovarian carcinoma and serous borderline ovarian tumors. ET/HT can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer and is probably allowed after ER/PR-negative breast cancer.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2024.2418503","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The specific Italian Group of Study of the Menopause formulated a consensus opinion on the use of estrogen therapy (ET) or combined estro-progestin hormone therapy (HT) after breast and gynecological cancers. This consensus is based on the risk of recurrence of the specific cancer during ET/HT, the presence of steroid receptors in cancer cells, the use of adjuvant hormone therapies and data on the use of ET/HT after cancer. The following positions were reached. ET/HT can be used after vulvar cancers and melanoma, but with great caution after the rare adenocarcinomas. ET/HT can be used after cervical cancer, but ET should be used with caution after adenocarcinomas. ET/HT can be used after International Federation of Obstetrics and Gynecology (FIGO) stage I-II estrogen-dependent endometrial cancers, except in Black women, and can probably be used after estrogen-independent endometrial cancers. ET/HT cannot be administered or should be used with great caution after most uterine sarcomas. ET/HT can probably be used after ovarian neoplasms except for granulosa cell tumors, and with great caution after low-grade serous ovarian carcinoma and serous borderline ovarian tumors. ET/HT can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer and is probably allowed after ER/PR-negative breast cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌和妇科癌症术后的全身激素治疗:意大利专家组的共识意见。
意大利更年期研究小组就乳腺癌和妇科癌症术后使用雌激素疗法(ET)或雌孕激素联合疗法(HT)达成了共识。该共识基于 ET/HT 期间特定癌症的复发风险、癌细胞中类固醇受体的存在、辅助激素疗法的使用以及癌症后使用 ET/HT 的数据。会议达成了以下共识。外阴癌和黑色素瘤术后可以使用 ET/HT,但对于罕见的腺癌则要非常谨慎。宫颈癌术后可使用 ET/HT,但腺癌术后应慎用 ET。国际妇产科联盟(FIGO)Ⅰ-Ⅱ期雌激素依赖型子宫内膜癌(黑人妇女除外)可以使用 ET/HT,雌激素不依赖型子宫内膜癌可能也可以使用 ET/HT。大多数子宫肉瘤不能使用或应慎用 ET/HT。卵巢肿瘤(颗粒细胞瘤除外)可能可以使用 ET/HT,但低级别浆液性卵巢癌和浆液性边缘卵巢肿瘤则应慎用。雌激素受体(ER)/孕激素受体(PR)阳性乳腺癌患者可慎用 ET/HT,ER/PR 阴性乳腺癌患者可能可以使用 ET/HT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Climacteric
Climacteric 医学-妇产科学
CiteScore
1.70
自引率
7.10%
发文量
53
审稿时长
1 months
期刊介绍: Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women. Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments. The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.
期刊最新文献
Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion. Hyaluronic acid and erbium laser for the treatment of genitourinary syndrome of menopause. Low-dose and ultra-low-dose estradiol and dydrogesterone in postmenopause: an analysis by body mass index. Heartwired for change: advancing women's cardiovascular health. Physician-patient alignment on menopause-associated symptom burden: real-world evidence from the USA and Europe.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1